Alpha memo: creatine cognitive function adults endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either (a) rename the memo to accurately describe a single receipt's signal (e.g., Receipt 1 as a bounded null-finding in young healthy adults) and drop Receipt 2, or (b) reframe as a cross-design scoping note that explicitly labels Receipt 2 as an exercise trial where creatine is a nested, secondary factor — not a parallel creatine-cognition endpoint.
2. Identify and state the actual bounded alpha signal. If a population/endpoint split is claimed, name the specific endpoints that are comparable across the two designs and the directional finding for each.
3. Provide a one-paragraph synthesis explaining why Receipt 1 and Receipt 2 jointly (or do not jointly) support any claim, including how age, training status, and primary vs secondary role of creatine change the interpretation.
4. State limitations specific to this pair: small N in Receipt 1 (n=30), heterogeneous older-adult multi-arm trial in Receipt 2, no shared endpoint battery, no replication.
5. Add a brief search scope statement (databases searched, date, terms) consistent with alpha-memo standards.

Major issues

• Title/source alignment failure: memo title says 'creatine cognitive function adults endpoint split' but the two receipts are fundamentally non-comparable designs (RCT of creatine monotherapy in young adults vs. multi-arm RCT of resistance training ± creatine in older adults). Receipt 2 is not a creatine-on-cognition receipt — it is an exercise-modality trial in which creatine is a secondary, nested factor and the primary contrast is HL-VIRT-EB vs HL-VIRT-AQ vs control. Treating these as a 'population/endpoint split' misreads the designs.
• The 'alpha signal' is incoherent: Receipt 1 is a null finding for creatine on cognition in young adults; Receipt 2 reports broad improvements attributed primarily to training, with creatine as a complementary adjunct. There is no single bounded research signal that unites them — only the keyword 'creatine + cognition'. This is the exact keyword-match alignment failure the review rubric is designed to catch.
• Receipt 2 (2026, Exp Gerontol) full text is not accessible in the bundle excerpt; even so, the abstract makes clear creatine's cognitive contribution is described as 'complementary' inside an exercise trial, not an independent cognitive endpoint. Quoting its endpoint list (BDNF, F2-iso, GPx, IL-6, TNF-α) as if it spoke directly to 'creatine cognitive function' is overclaim.
• Population mismatch (young adults ~20–22 y vs older adults ~68 y) is acknowledged but then dismissed as a 'bounded split'; for cognitive endpoints, age is a primary effect modifier, not a cosmetic axis.

Minor issues

• Abstract is truncated mid-sentence ('(PS: CR10: 4%...;') and repeated verbatim across Evidence Landscape and Why this is surprising, indicating the memo was not finished/proofread.
• 'Why this is surprising' section asserts a 'bounded population/endpoint split' but never states what the split actually shows — the novelty claim is never cashed out.
• Caveats/falsifiers list generic guardrails ('reject if keyword match only') without applying them to the actual receipt pair, which is precisely a keyword match.
• No explicit search scope, no number of records screened, no inclusion criteria — atypical even for terse alpha memos.
• Gaps phrase 'a direct replication that measures both receipt endpoint families in the same target population' is the right idea but is the only forward statement and is generic.

Reviewer note

Reject. The submission fails the title/source alignment check at its core. Receipt 1 is a null-finding creatine monotherapy RCT in 30 young adults with cognitive + fNIRS endpoints. Receipt 2 is a six-arm resistance training modality trial in 103 older adults where creatine is one of several factors and exercise modality is the primary contrast. Framing these as a 'creatine cognitive function adults endpoint split' requires forcing a keyword match into a 'bounded research signal' that the designs do not actually share. The abstract is truncated and duplicated across sections, the synthesis never states what the split shows, and the caveats list generic guards without applying them. The source bundle contains excerpts that do not support the implied claim that creatine has a comparable, isolable cognitive effect across young and older adults. The only honest move is to rename/scope down to one receipt or relabel the artifact as a cross-design scoping note (not an evidence map with an alpha signal).

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis